These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 9231312

  • 21. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
    Tundo A, Salvati L, Busto G, Di Spigno D, Falcini R.
    J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971
    [Abstract] [Full Text] [Related]

  • 22. Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder.
    Storch EA, Bussing R, Small BJ, Geffken GR, McNamara JP, Rahman O, Lewin AB, Garvan CS, Goodman WK, Murphy TK.
    Behav Res Ther; 2013 Dec; 51(12):823-9. PubMed ID: 24184429
    [Abstract] [Full Text] [Related]

  • 23. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder.
    Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowtiz MR, Lydiard B.
    Int Clin Psychopharmacol; 1995 Jun; 10(2):57-65. PubMed ID: 7673657
    [Abstract] [Full Text] [Related]

  • 24. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.
    Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, Campeas R, Hahn CG, Petkova E.
    Am J Psychiatry; 2008 May; 165(5):621-30. PubMed ID: 18316422
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of combination of fluoxetine and cognitive behavioral therapy and fluoxetine alone for the treatment of obsessive compulsive disorder.
    Giasuddin NA, Nahar JS, Morshed NM, Balhara YP, Sobhan MA.
    Pak J Pharm Sci; 2013 Jan; 26(1):95-8. PubMed ID: 23261733
    [Abstract] [Full Text] [Related]

  • 26. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder.
    Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K.
    Arch Gen Psychiatry; 1995 Apr; 52(4):289-95. PubMed ID: 7702445
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM, Ringold AL, Elliott MA.
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L, Çetinkaya N, Selvi Y, Atli A.
    Compr Psychiatry; 2011 Jul; 52(5):556-61. PubMed ID: 21109243
    [Abstract] [Full Text] [Related]

  • 33. Sertraline Treatment of Nonresponders to Extended Cognitive-Behavior Therapy in Pediatric Obsessive-Compulsive Disorder.
    Skarphedinsson G, Weidle B, Ivarsson T.
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):574-9. PubMed ID: 26348088
    [Abstract] [Full Text] [Related]

  • 34. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L.
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [Abstract] [Full Text] [Related]

  • 35. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW, Morton WA, Lydiard RB.
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
    Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC.
    Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder.
    Neziroglu F, Yaryura-Tobias JA, Walz J, McKay D.
    J Child Adolesc Psychopharmacol; 2000 Jan; 10(4):295-306. PubMed ID: 11191690
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. An open trial and discontinuation study of fluoxetine in children and adolescents with obsessive-compulsive disorder.
    Semerci ZB, Unal F.
    Turk J Pediatr; 2001 Jan; 43(4):323-8. PubMed ID: 11765163
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.